Elsevier

Human Pathology

Volume 30, Issue 7, July 1999, Pages 803-808
Human Pathology

Original contribution
Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: Correlation with 3q27 and 18q21 chromosomal abnormalities

https://doi.org/10.1016/S0046-8177(99)90141-7Get rights and content

Abstract

The bcl-2 gene on chromosome 18 at q21 and the bcl-6 gene on chromosome 3 at q27 are both highly regulated during B-cell differentiation and show an inverse relationship of expression in the normal secondary lymphoid follicle. The objective of this study was to investigate the relationship between bcl-2 and bcl-6 protein expression and the relationship between protein expression and the corresponding chromosomal alterations in malignant lymphomas, including those associated with the germinal center. Expression of bcl-2 and bcl-6 proteins was studied in 55 cases of diffuse large B-cell lymphoma (DLBCL) and 21 cases of follicular lymphoma (FL), and the results correlated with the presence of t(14;18) and 3q27 abnormalities in a subset of 52 cases with cytogenetic analysis. These cases were selected to represent a spectrum of nodal and extranodal lymphomas, including those with and without a t(14;18). It was shown that the neoplastic cells in 71% of DLBCLs and 100% of FLs expressed bcl-6 protein. Expression of bcl-6 was seen more frequently in diffuse large B-cell lymphomas with large noncleaved morphology compared with immunoblastic morphology (82% v 27%, P = .0015), but failed to correlate with 3q27 abnormalities. Thirty-eight percent of cases with 3q27 abnormalities were bcl-6 protein negative, whereas 85% of cases without a 3q27 abnormalities were bcl-6 protein positive. Expression of bcl-2 protein was shown in 51% DLBCLs (nodal v extranodal, 71% v 30%, P = .012). bcl-2 protein was expressed in 89% of FLs with t(14;18), in contrast to 25% of FLs without t(14;18) (P = .016). In DLBCL and FL with t(14;18), the most common pattern of expression was bcl-2+bcl-6+. In lymphomas without t(14;18), there was not an inverse relationship between bcl-2 and bcl-6 protein expression. In conclusion, these data suggest that mechanisms other than gene rearrangements can deregulate bcl-2 and bcl-6 expression in lymphomas, and there does not appear to be an inverse relationship between these two proteins as seen in the normal germinal center.

References (37)

  • SJ Korsmeyer

    Bcl-2 initiates a new category of oncogenes: Regulators of cell death

    Blood

    (1992)
  • LM Larocca et al.

    The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells

    Blood

    (1998)
  • O Monni et al.

    BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma

    Blood

    (1997)
  • R Liang et al.

    High incidence of BCL-6 gene rearrangement in diffuse large B-cell lymphoma of primary gastric origin

    Cancer Genet Cytogenet

    (1997)
  • M Engelhard et al.

    Subclassification of diffuse large B-cell lymphomas according to the Kiel Classification: Distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor

    Blood

    (1997)
  • C-C Chang et al.

    BCL-6, a POZzinc-finger protein, is a sequence-specific transcriptional repressor

  • BH Ye et al.

    The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation

    Nature Genet

    (1997)
  • AL Dent et al.

    Control of inflammation, cytokine expression, and germinal center formation by BCL-6

    Science

    (1997)
  • Cited by (0)

    View full text